Starting July 1, 2026, the Medicare GLP-1 Bridge (a temporary CMS demonstration) lets eligible Part D members pay a flat $50 a month for certain GLP-1 weight-loss drugs, including Wegovy, the Zepbound KwikPen, and Foundayo. It runs through December 31, 2027, and requires meeting BMI-based clinical criteria.
For the first time, Medicare will help pay for GLP-1 medications used specifically for weight loss. Starting July 1, 2026, a temporary program called the Medicare GLP-1 Bridge lets eligible Part D members fill certain weight-loss drugs for a flat $50 a month, a fraction of the more than $1,000 these medications can cost out of pocket. Here's who qualifies, which drugs are included, and how St. Augustine seniors can prepare.
The figures and dates here reflect federal guidance as of June 11, 2026. The Bridge is a new, temporary demonstration, and the program that's meant to follow it is still taking shape, so details can change. Always confirm specifics with medicare.gov or with us before making a decision.
What is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a temporary demonstration run by the Centers for Medicare and Medicaid Services (CMS) that gives eligible Part D members access to certain GLP-1 weight-loss drugs for $50 a month. It runs from July 1, 2026 through December 31, 2027.
GLP-1 medications (the family of drugs that includes Wegovy and Zepbound) have been widely covered for type 2 diabetes but, until now, not for weight loss alone. By law, Medicare’s standard Part D benefit hasn’t been allowed to pay for drugs used purely for weight management. The Bridge is CMS’s way of opening access without rewriting that rule: it sits outside the normal Part D benefit, so individual drug plans don’t carry the financial risk for these prescriptions.
For a St. Augustine retiree who’s been quoted four figures a month at the pharmacy counter, the practical headline is simple. A medication that was out of reach may now cost about $50 a month, as long as you’re enrolled in a Part D plan and meet the clinical criteria.
Which weight-loss drugs are covered, and which aren’t?
The Bridge covers a specific, short list of GLP-1 drugs when they’re prescribed to reduce body weight and keep it off. It does not cover every GLP-1 medication on the market.
| Medication | Covered under the Bridge for weight loss? | Notes |
|---|---|---|
| Wegovy (semaglutide) | Yes, all formulations | Includes both the injection and the oral tablet |
| Zepbound (tirzepatide) | Yes, KwikPen only | Other Zepbound forms are not included in the Bridge |
| Foundayo | Yes, all formulations | An oral GLP-1 option included in the demonstration |
| Ozempic, Mounjaro, Rybelsus | No, not for weight loss under the Bridge | May still be covered by your Part D plan for type 2 diabetes |
This distinction trips people up, so it’s worth being clear: Ozempic and Mounjaro are approved for diabetes, not weight loss, and the Bridge doesn’t change how they’re covered. If you take one of those for diabetes, your existing Part D coverage continues as before.
Who qualifies for the $50 copay?
To use the Bridge, you need two things: enrollment in a Medicare Part D plan (either a standalone drug plan or a Medicare Advantage plan that includes drug coverage) and a provider who confirms you meet the clinical criteria. Those criteria are built around your body mass index (BMI) and related health conditions.
One point to know up front: the Bridge is specifically for reducing excess body weight. If you can already get a GLP-1 covered through your regular Part D benefit for another reason, such as type 2 diabetes, you would receive it that way instead and aren’t eligible through the Bridge.
| Your situation | BMI threshold | Qualifying condition required |
|---|---|---|
| BMI alone | 35 or higher | None required |
| BMI plus a heart or kidney condition | 30 or higher | Heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease (stage 3a or higher) |
| BMI plus elevated cardiovascular risk | 27 or higher | Prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease |
Your prescriber also has to confirm that you’re using the medication alongside ongoing lifestyle modification: structured nutrition and physical activity consistent with the drug’s FDA-approved label. That’s not a hoop for its own sake. The program is built around the evidence that GLP-1 drugs work best when they’re paired with real, sustained lifestyle change.
What the $50 copay does and doesn’t include
The $50 is genuinely a flat copay. It doesn’t climb as your dose increases, and it’s the same whether you fill Wegovy, the Zepbound KwikPen, or Foundayo. But because the Bridge sits outside the normal Part D benefit, the copay behaves differently from your other prescriptions, and that surprises people.
The $50 Bridge copay works outside your normal Part D math:
- It does not count toward your Part D deductible.
- It does not count toward your annual out-of-pocket cap on prescription drugs, which is $2,100 in 2026.
- Extra Help (the low-income subsidy) does not lower the $50 for Bridge prescriptions.
- The copay stays at $50 a month even as your prescribed dose goes up.
For most people, $50 a month is still a dramatic improvement over paying full price. The catch worth flagging is for beneficiaries who rely on Extra Help to keep their drug costs near zero. For them, $50 a month is a real expense the subsidy won’t offset. If that’s your situation, it’s worth running the numbers before you start.
How do you actually get it?
The path runs through your doctor, not your insurance plan. Here’s the sequence.
Talk with your doctor
Confirm your BMI and whether you have a qualifying condition. Your provider decides whether a GLP-1 drug is clinically appropriate for you, a conversation many local patients are already having with their care teams at Baptist Health, Flagler Health, and other area systems.
Your provider submits the request
The prescriber attests that you meet the criteria and submits a prior authorization through the central processor CMS set up for the Bridge. This is handled provider-to-program, not through your individual drug plan.
Fill it at the pharmacy and pay $50
Once approved, you fill the prescription and pay the flat $50. You don't have to switch plans or hunt for a special pharmacy: the Bridge runs through a central processor CMS set up, outside your individual drug plan, so your Part D plan doesn't have to opt in and pharmacies can bill it electronically.
Pair it with lifestyle change
Staying engaged in structured nutrition and physical activity isn't optional paperwork. It's part of what makes the medication work and part of what the program requires to keep your eligibility.
What happens when the Bridge ends in 2027?
This is the part to plan around. The Bridge is temporary by design, and it stops on December 31, 2027. CMS built a longer-term program (the BALANCE Model) to carry GLP-1 coverage forward in Part D after that. But that rollout has hit delays and uncertain plan participation, and as the Kaiser Family Foundation has reported, there’s no guaranteed path for Medicare GLP-1 weight-loss coverage once the Bridge expires.
What that means for you, practically: don’t assume the $50 price continues automatically into 2028. If you start a GLP-1 drug through the Bridge, treat your Part D coverage as something to review every year during the Annual Enrollment Period (October 15 to December 7) so you’re not caught off guard if the rules or your plan’s participation change.
How this fits your Medicare picture in St. Augustine
A new program with shifting rules, a drug list with exceptions, eligibility tied to clinical criteria, and a copay that behaves unlike your other prescriptions: this is exactly the kind of decision where a single phone call saves a lot of guessing. At Duncan Market Insurance, Carolyn Duncan has spent 20-plus years as an independent broker helping St. Augustine and St. Johns County seniors line up the coverage that actually fits their situation.
We can’t write your prescription. That’s your doctor’s call. But we can confirm you’re enrolled in a Part D plan (the coverage requirement for the Bridge), walk through what the $50 copay means against the rest of your drug costs, and make sure you’re positioned for the Annual Enrollment Period so a 2027 change doesn’t surprise you. If you’re weighing your broader options, our guide to Medicare Advantage vs. Medigap in Florida is a good companion read, and our piece on what to look for in an insurance broker explains how an advocate who works for you, not a carrier, approaches questions like this one.
Ready to check how the new GLP-1 rules fit your plan?
The Medicare GLP-1 Bridge could make a medication that felt impossible suddenly affordable, or it could come with caveats that matter for your budget. A consultation with Duncan Market Insurance is a no-pressure, no-obligation conversation. We’ll help you read the fine print, confirm you meet the eligibility rules, and decide your next step with clear eyes.
Book a consultation → · Call 904-217-8368
Sources
- Medicare GLP-1 Bridge, Centers for Medicare & Medicaid Services
- Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries, CMS Newsroom
- Medicare GLP-1 Bridge: Information for Medicare Beneficiaries, CMS
- What to Know About the BALANCE Model for GLP-1s and the Medicare GLP-1 Bridge, KFF
- GLP-1 Weight-Loss Drug Demonstration Begins July 2026, Medicare Rights Center
- Medicare.gov
Key takeaways
Frequently asked questions
Does Medicare cover Ozempic or Wegovy for weight loss in 2026?
Through the Medicare GLP-1 Bridge starting July 1, 2026, eligible Part D members can get Wegovy (all formulations), the Zepbound KwikPen, and Foundayo for weight loss at a flat $50 monthly copay. Ozempic and Mounjaro are not covered for weight loss under the Bridge, though Part D may still cover them for type 2 diabetes.
How much do GLP-1 weight-loss drugs cost under Medicare's Bridge program?
Eligible beneficiaries pay a flat $50 per month, regardless of which covered drug or dose they take. Without coverage, these medications often run more than $1,000 a month. The $50 copay stays the same even as your prescribed dose increases over time.
Who qualifies for the Medicare GLP-1 Bridge?
You must be enrolled in a Medicare Part D plan and meet clinical criteria confirmed by your provider: a BMI of 35 or higher; a BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure, or moderate-to-advanced chronic kidney disease (stage 3a or higher); or a BMI of 27 or higher with prediabetes, a prior heart attack, a prior stroke, or peripheral artery disease.
Does the $50 GLP-1 copay count toward my Medicare drug out-of-pocket cap?
No. The $50 copay does not count toward your Part D deductible and does not count toward the annual out-of-pocket cap on prescription drugs ($2,100 in 2026). Low-income subsidy (Extra Help) cost-sharing assistance also does not apply to Bridge prescriptions.
What happens to Medicare GLP-1 coverage after 2027?
The Bridge is temporary and ends December 31, 2027. CMS designed a longer-term BALANCE Model to follow it in Part D, but that rollout has faced delays and uncertain plan participation. Coverage after the Bridge is not guaranteed, so review your Part D plan during each Annual Enrollment Period.
Not connected with or endorsed by the U.S. Government or the Federal Medicare Program.
